Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-Epratuzumab for Relapsed/Refractory CD22+ B-ALL
NCT01354457Phase 2Unknown
- Sponsor
- CHU de Nantes
- Start
- Nov 2010
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 90Y-epratuzumab tetraxetan in B cell acute lymphoblastic leukemia (B-ALL), sponsored by CHU de Nantes. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
90Y-epratuzumab tetraxetan
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT01354457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01354457.